The requirement of Nrf2 for the protective effect of pharmacological Nrf2 inducers is only rarely assessed, and has only been assessed in acute models of Parkinson’s disease, Huntington’s disease and multiple sclerosis. The gene discussed is NFE2L2; the disease is juvenile Huntington disease.